

Pharmaceutical Policies Updates Effective April 1, 2021

To view all current MVP Health Care® (MVP) Medical policies, *Sign In* at **mvphealthcare.com** and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** Denotes a new policy
- **Updated** Updated policies have content changes that may affect coverage criteria for services and/or drugs
- Reviewed/No Changes— Policies that have been reviewed but have no content change
- **Archived** Denotes a policy that is no longer active

The following policies are effective April 1, 2021 and will be available for viewing on or before February 1, 2021. Hard copies of the policies are available upon request.

| Pharmaceutical Policy Name | Status |
|---|----------|
| Male Hypogonadism | Updated |
| Metformin ER | Reviewed |
| Growth Hormone Therapy (effective January 1, 2021) | Updated |
| Phenylketonuria Agents | Updated |
| Infertility Drug Therapy (Commercial/Marketplace) (effective February 1, 2021) | Updated |
| Infertility Drug Therapy (Medicaid/HARP) | Reviewed |
| Acthar | Updated |
| Jynarque (effective February 1, 2021) | New |
| Physician Prescription Eligibility | Reviewed |
| Prescribers Treating Self or Family Members | Updated |
| Mail Order | Reviewed |
| Migraine Agents | Updated |
| Zinplava | Updated |
| Lyme Disease/IV Antibiotic Treatment (effective February 1, 2021) | Updated |
| Erythropoiesis Stimulating Agents (ESAs) | Reviewed |
| Eylea (aflibercept) Intravitreal (effective February 1, 2021) | New |
| Intranasal Corticosteroids (effective January 1, 2021) | Updated |
| Calcitonin Gene-Related Peptide (CGRP) Antagonists (effective February 1, 2021) | Updated |
| Orphan Drug(s) and Biologicals | Updated |

To view all communications, visit mvphealthcare.com/FastFax

To receive future FastFax messages by email, contact your Professional Relations Representative

